| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Cariprazine |
| Brand | Reagila® |
| Indication | For the treatment of schizophrenia in adult patients. |
| Assessment Process | |
| Rapid review commissioned | 27/11/2018 |
| Rapid review completed | 19/12/2018 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cariprazine (Reagila®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations; June 2019
